|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii1–iii9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Benson AB III, Venook AP, Cederquist L,
Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC,
Fichera A, et al: Colon cancer, version 1.2017, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
15:370–398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Benson AB, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: Rectal vancer, version 2.2018, NCCN Clinical
Practice Guidelines in Oncology. J Natl Compr Canc Netw.
16:874–901. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoshino T, Arnold D, Taniguchi H,
Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh
KH, et al: Pan-Asian adapted ESMO consensus guidelines for the
management of patients with metastatic colorectal cancer: A
JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann
Oncol. 29:44–70. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: The PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ingraham HA, Tseng BY and Goulian M:
Nucleotide levels and incorporation of 5-fluorouracil and uracil
into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol.
21:211–216. 1982.PubMed/NCBI
|
|
9
|
Glazer RI and Lloyd LS: Association of
cell lethality with incorporation of 5-fluorouracil and
5-fluorouridine into nuclear RNA in human colon carcinoma cells in
culture. Mol Pharmacol. 21:468–473. 1982.PubMed/NCBI
|
|
10
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Drake JC, Allegra CJ and Johnston PG:
Immunological quantitation of thymidylate
synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with
the monoclonal antibody TS 106. Anticancer Drugs. 4:431–435. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mori R, Futamura M, Tanahashi T, Tanaka Y,
Matsuhashi N, Yamaguchi K and Yoshida K: 5FU resistance caused by
reduced fluoro-deoxyuridine monophosphate and its reversal using
deoxyuridine. Oncol Lett. 14:3162–3168. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mori R, Yoshida K, Futamura M, Suetsugu T,
Shizu K, Tanahashi T, Tanaka Y, Matsuhashi N and Yamaguchi K: The
inhibition of thymidine phosphorylase can reverse acquired
5FU-resistance in gastric cancer cells. Gastric Cancer. 22:497–505.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsujimoto H, Tsukioka S, Ono S, Sakamoto
E, Sakamoto K, Tsuta K, Nakagawa F, Saito H, Uchida J, Kiniwa M and
Fukushima M: Effect of leucovorin on the antitumor efficacy of the
5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts
with various expression levels of thymidylate synthase. Oncol Lett.
1:973–980. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jilek JL, Tu MJ, Zhang C and Yu AM:
Pharmacokinetic and pharmacodynamic factors contribute to synergism
between Let-7c-5p and 5-fluorouracil in inhibiting hepatocellular
carcinoma cell viability. Drug Metab Dispos. 48:1257–1263. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kodera Y, Ito S, Fujiwara M, Mochizuki Y,
Nakayama G, Ohashi N, Koike M, Yamamura Y and Nakao A: Gene
expression of 5-fluorouracil metabolic enzymes in primary gastric
cancer: Correlation with drug sensitivity against 5-fluorouracil.
Cancer Lett. 252:307–313. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Isshi K, Sakuyama T, Gen T, Nakamura Y,
Kuroda T, Katuyama T and Maekawa Y: Predicting 5-FU sensitivity
using human colorectal cancer specimens: Comparison of tumor
dihydropyrimidine dehydrogenase and orotate phosphoribosyl
transferase activities with in vitro chemosensitivity to 5-FU. Int
J Clin Oncol. 7:335–342. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boskos CS, Liacos C, Korkolis D, Aygerinos
K, Lamproglou I, Terpos E, Stoupa E, Baltatzis G, Beroukas K,
Papasavvas P, et al: Thymidine phosphorylase to dihydropyrimidine
dehydrogenase ratio as a predictive factor of response to
preoperative chemoradiation with capecitabine in patients with
advanced rectal cancer. J Surg Oncol. 102:408–412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mori T, Ohue M, Takii Y, Hashizume T, Kato
T, Kotake K, Sato T and Tango T: Factors predicting the response to
oral fluoropyrimidine drugs: A phase II trial on the
individualization of postoperative adjuvant chemotherapy using oral
fluorinated pyrimidines in stage III colorectal cancer treated by
curative resection (ACT-01 Study). Oncol Rep. 29:437–444. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fanciullino R, Evrard A, Cuq P, Giacometti
S, Peillard L, Mercier C, Aubert C, Milano G and Ciccolini J:
Genetic and biochemical modulation of 5-fluorouracil through the
overexpression of thymidine kinase: An in-vitro study. Anticancer
Drugs. 17:463–470. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshino T, Mizunuma N, Yamazaki K, Nishina
T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, et
al: TAS-102 monotherapy for pretreated metastatic colorectal
cancer: A double-blind, randomised, placebo-controlled phase 2
trial. Lancet Oncol. 13:993–1001. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Emura T, Nakagawa F, Fujioka A, Ohshimo H,
Yokogawa T, Okabe H and Kitazato K: An optimal dosing schedule for
a novel combination antimetabolite, TAS-102, based on its
intracellular metabolism and its incorporation into DNA. Int J Mol
Med. 13:249–255. 2004.PubMed/NCBI
|
|
24
|
Tanaka N, Sakamoto K, Okabe H, Fujioka A,
Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K,
et al: Repeated oral dosing of TAS-102 confers high trifluridine
incorporation into DNA and sustained antitumor activity in mouse
models. Oncol Rep. 32:2319–2326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilson PM, Danenberg PV, Johnston PG, Lenz
HJ and Ladner RD: Standing the test of time: Targeting thymidylate
biosynthesis in cancer therapy. Nat Rev Clin Oncol. 11:282–298.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Emura T, Nakagawa F, Fujioka A, Ohshimo H
and Kitazato K: Thymidine kinase and thymidine phosphorylase level
as the main predictive parameter for sensitivity to TAS-102 in a
mouse model. Oncol Rep. 11:381–387. 2004.PubMed/NCBI
|
|
27
|
Yoshino T, Yamazaki K, Shinozaki E,
Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K,
Sugimoto N, et al: Relationship between thymidine kinase 1
expression and Trifluridine/Tipiracil therapy in refractory
metastatic colorectal cancer: A pooled analysis of 2 randomized
clinical trials. Clin Colorectal Cancer. 17:e719–e732. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kataoka Y, Iimori M, Niimi S, Tsukihara H,
Wakasa T, Saeki H, Oki E, Maehara Y and Kitao H: Cytotoxicity of
trifluridine correlates with the thymidine kinase 1 expression
level. Sci Rep. 9:79642019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Toden S, Okugawa Y, Jascur T, Wodarz D,
Komarova NL, Buhrmann C, Shakibaei M, Boland CR and Goel A:
Curcumin mediates chemosensitization to 5-fluorouracil through
miRNA-induced suppression of epithelial-to-mesenchymal transition
in chemoresistant colorectal cancer. Carcinogenesis. 36:355–367.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Denise C, Paoli P, Calvani M, Taddei ML,
Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, et
al: 5-fluorouracil resistant colon cancer cells are addicted to
OXPHOS to survive and enhance stem-like traits. Oncotarget.
6:41706–41721. 2015. View Article : Google Scholar : PubMed/NCBI
|
